To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Life science fund bypasses early-stage investment jitters
MVM has closed its second fund at £100m, £40m above its original target, highlighting sustained investor appetite for the biotechnology sector.
